Your Messages Inbox
Your Article Summary
See Latest ArticlesAlcon to Acquire Swiss Biotechnology Firm, ESBATech AG
Alcon, 09/14/09
Alcon announced that it has entered into a definitive agreement to acquire ESBATech AG, a Swiss biotechnology company. Alcon will pay ESBATech shareholders $150 million in cash at closing, plus contingent payments of up to $439 million based upon the achievement of future research and development milestones that would be expected to create value for Alcon. ESBATech is a clinical–stage biotechnology company that has been developing a pipeline of proprietary single–chain antibody fragment therapeutics for topical and local delivery for safe and convenient therapy.
Today in Biotechnology...keeping you current
Receive free subspecialty "5-minute updates" via email
ImmunoGen, Inc. Announces Clinical Data Presentations on Three TAP Compounds at Upcoming ASH Annual Meeting and Exposition
ImmunoGen, Inc., 11/25/09
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09
Expanding The Biopharmaceutical Industry's Involvement In Fighting Neglected Diseases
Health Affairs, 11/19/09
Article Search
Sponsor